Abiomed nearly triples fiscal Q2 profits, crushes earnings expectations
Abiomed (NSDQ:ABMD) today said that its fiscal second-quarter profits nearly tripled and crushed the consensus earnings forecast on a nearly 30% sales increase.
The Danvers, Mass.-based percutaneous heart pump maker posted profits of $24.5 million, or 54¢ per share, on sales of $132.8 million for the three months ended Sept. 30, for a bottom-line gain if 176.1% on sales growth of 29.0% compared with fiscal Q2 2017.
Analysts on Wall Street were looking for EPS of 38¢ on sales of $131.1 million.
“This quarter, we set new records for supporting patients in the U.S. and Germany and we continue to observe improved clini...
Source: Mass Device - October 26, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Cardiac Assist Devices MassDevice Earnings Roundup Wall Street Beat Abiomed Source Type: news
TCT 2017: Rich in Clinical Trials, Star Power TCT 2017: Rich in Clinical Trials, Star Power
Oscar-winner Tom Hanks headlines a conference that will feature clinical trials looking at management of left main disease, cardiogenic shock, and bioabsorbable scaffolds.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 17, 2017 Category: Consumer Health News Tags: Cardiology News Source Type: news
MAUDE: Post-TAVR Leaflet Thrombosis Not Benign MAUDE: Post-TAVR Leaflet Thrombosis Not Benign
While post-TAVR leaflet thrombosis can cause valve dysfunction or even cardiogenic shock and death, the question remains whether there ' s justification for routine anticoagulation given its inherent risks.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 8, 2017 Category: Consumer Health News Tags: Cardiology News Source Type: news
Stenting Safe, More Popular for Oldest Old
(MedPage Today) -- Cardiogenic shock, no-reflow still problems in 90-year-olds (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - July 5, 2017 Category: Cardiology Source Type: news
Abiomed touts survival benefits in Impella 2.5 cardiogenic shock PCI treatment study
Abiomed (NSDQ:ABMD) today released results from a study of its Impella 2.5 heart pump examining the use of the device in patients with acute myocardial infarction complicated by cardiogenic shock, touting survival benefits associated with the device.
Results from the Danvers, Mass.-based company’s study were published in the Journal of Interventional Cardiology.
Data from the 36-patient retrospective study came from real-world outcomes with the Impella 2.5 during percutaneous coronary interventions on unprotected left main coronary arteries, Abiomed said. The study aimed to analyze whether the initiation of hemodyna...
Source: Mass Device - July 3, 2017 Category: Medical Devices Authors: Fink Densford Tags: Cardiovascular Clinical Trials Abiomed Source Type: news
The Medical Emergency Of Otto Warmbier
All that the doctors who treated Cincinnati, Ohio resident Otto Warmbier knew is what they had seen or maybe read in the news. They knew he had just been released on June 13 from imprisonment in North Korea where he had been held by for more than 17 months. He had been sentenced in March 2016 to 15 years of hard labor for allegedly removing a propaganda poster from a wall at a Pyongyang hotel where he had been staying. The University of Virginia honors student had been visiting the authoritarian state during a five-day trip with a group called Young Pioneer Tours, which is a group out of China – an important note.
Ot...
Source: Healthy Living - The Huffington Post - June 22, 2017 Category: Consumer Health News Source Type: news
Datascope joins Maquet countersuit against Abiomed
Getinge‘s (PINK:GETI B) Datascope said today it is filing a motion to join fellow Getinge company Maquet‘s patent infringement case against Abiomed (NSDQ:ABMD).
The Wayne, N.J.-based company said it is asserting counterclaims which allege that Abiomed engaged in false advertising to promote that its Impella device was superior to Datascope’s intra-aortic baloon pumps.
Datascope said that, simultaneously, Maquet will be expanding the infringement case by alleging that most Impella models infringe upon 3 Maquet patents, bringing the total number of patents in the suit to 6.
In Datascope’s counterclai...
Source: Mass Device - June 16, 2017 Category: Medical Devices Authors: Fink Densford Tags: Legal News Patent Infringement Abiomed Datascope Corp. Getinge Maquet Cardiovascular LLC Source Type: news
Suicide attempt with self-made Taxus baccata leaf capsules: survival following the application of extracorporeal membrane oxygenation for ventricular arrythmia and refractory cardiogenic shock - Vardon Bounes F, Tardif E, Ruiz S, Gallart JC, Conil JM, Delmas C.
We present a case report of a patient who attempted suicide after T. baccata... (Source: SafetyLit)
Source: SafetyLit - May 19, 2017 Category: International Medicine & Public Health Tags: Poisoning Source Type: news
Abiomed launches 3rd-gen Impella CP heart pump
Abiomed (NSDQ:ABMD) said today it launched a 3rd generation Impella CP heart pump, touting new features and improved performance with the new model.
The Danvers, Mass.-based company said that the 3rd-gen device includes new features that allow for better care during percutaneous coronary interventions in high risk patients and for patients being treated with the Impella in the ICU.
“The ability to introduce the Impella device simply and swiftly even in the presence of challenging femoral or iliac arteries will be valuable for interventional cardiologists caring for high-risk patients during PCI and for those in cardi...
Source: Mass Device - May 9, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Cardiac Assist Devices Cardiovascular Abiomed Source Type: news
Abiomed dips on missed Q4 earnings, despite sales beat
Share prices for Abiomed (NSDQ:ABMD) dipped today after the company reported fiscal 4th-quarter earnings that missed expectations, despite a top-line gain of nearly 33%.
The Danvers, Mass.-based heart pump maker posted profits of $14.9 million, or 33¢ per share, on sales of $124.7 million for the 3 months ended March 31, for a bottom-line increase of 35.5% on sales growth of 32.7% compared with Q4 2016.
But analysts on Wall Street were looking for earnings per share of 35¢; Abiomed topped the consensus Street estimate for sales by more than $2 million.
Full-year profits were $52.1 million, or $1.17 per share, on sales o...
Source: Mass Device - May 4, 2017 Category: Medical Equipment Authors: Brad Perriello Tags: Cardiac Assist Devices MassDevice Earnings Roundup Wall Street Beat Abiomed Source Type: news
6 Variables Can Predict Mortality Risk in Cardiogenic Shock
Variables from Intraaortic Balloon Pump in Cardiogenic Shock trial ID short - term mortality risk (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - April 13, 2017 Category: Respiratory Medicine Tags: Cardiology, Internal Medicine, Critical Care, Emergency Medicine, Nursing, Pulmonology, Journal, Source Type: news
Abiomed doubles Danvers footprint
Abiomed (NSDQ:ABMD) today opened its expanded headquarters in Danvers, Mass., which more than doubles its footprint in the Bay State.
Gov. Charlie Baker helped Abiomed CEO Mike Minogue and patient survivors to cut the ribbon on the $40 million, 160,000-square-foot HQ north of Boston.
Abiomed makes the Impella line of percutaneous heart pumps, which are designed to provide cardiac support to heart failure patients during PCI procedures. The expansion adds new R&D and manufacturing facilities and a clinical training facility called the Heart Recovery Institute.
“Today we recognize 35 years of dedication and hard wo...
Source: Mass Device - March 30, 2017 Category: Medical Equipment Authors: Brad Perriello Tags: Cardiac Assist Devices Wall Street Beat Abiomed Source Type: news
Impella Pump Takes Positive Turn in Cardiogenic Shock Study Impella Pump Takes Positive Turn in Cardiogenic Shock Study
After the Impella heart pump showed no added benefit in cardiogenic shock over less costly balloon pumps in prior studies, applying best practices appears to be paying off with the device.Heartwire from Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - March 27, 2017 Category: Cardiology Tags: Cardiology News Source Type: news
MassDevice.com +5 | The top 5 medtech stories for December 7, 2016
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Get this in your inbox everyday by subscribing to our newsletters.
5. Baxter releases infusion pump programming software
Baxter launched its Sigma Spectrum Safety Management System this week at the American Society of Health-System Pharmacists meeting. The infusion pump system consists of an anal...
Source: Mass Device - December 7, 2016 Category: Medical Equipment Authors: MassDevice Tags: News Well Plus 5 Source Type: news
FDA adds high-risk indication to Abiomed ’ s Impella CP heart pump
Abiomed (NSDQ:ABMD) said today that it won an expanded indication from the FDA for its Impella CP heart pump for high-risk patients.
The Impella CP device, which won pre-market approval earlier this year for up to 4 hours of treating patients for cardiogenic shock after acute myocardial infarction or cardiac surgery, can now be used to for up to 6 hours during high-risk percutaneous coronary interventions, Danvers, Mass.-based Abiomed said.
“This latest approval for Impella expands the hemodynamic options for the cardiovascular community to effectively revascularize severely ill patients who have limited options a...
Source: Mass Device - December 7, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Cardiac Assist Devices Food & Drug Administration (FDA) Regulatory/Compliance Abiomed Inc. Source Type: news
